Korsana Biosciences
PublicKorsana Biosciences is now publicly traded
The data on this page reflects Korsana Biosciences's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
PIPE
Apr 1, 2026
Total Funding Raised
$730M
Company Overview
Korsana Biosciences is a biotechnology company developing brain-penetrant therapeutics for neurodegenerative diseases using its proprietary blood-brain barrier shuttle platform.
AI Layer
Non-AI
Keywords
Korsana Biosciences Comparables
Compare Korsana Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| NanoNewron, Inc. | 81% | |
| AbbVie | 78% | |
| SciNeuro Pharmaceuticals | 76% |
For institutional investors. Book with your work email.
Korsana Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| PIPE | Apr 1, 2026 | ||||
| Seed | Feb 18, 2026 | ||||
| Series A | Sep 1, 2025 | ||||
| Seed | Dec 1, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Korsana Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | PIPE, Seed, Series A |
| RA Capital Management | PIPE |
| TCG Crossover | PIPE, Seed, Series A |
| Forbion | PIPE |
| Fairmount Funds Management | Seed, PIPE |
| Commodore Capital | PIPE |
| Kalehua Capital Management | PIPE |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingSep 8, 2026
Korsana Biosciences, Inc. receives $380M in gross proceeds through a private financing of common stock and pre-funded warrants immediately before the merger closing in Massachusetts on Sep 8th '26, led by Fairmount and Venrock Healthcare Capital Partners with participation from General Atlantic and other investors to support operations through 2029 and advance KRSA-028 clinical milestones.
For institutional investors. Book with your work email.
Korsana Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.